Christine Silverstein

CFO at Excision BioTherapeutics

Silverstein is a seasoned corporate finance executive with invaluable experience across both private and public biopharmaceutical companies. Most recently, she served as Chief Financial Officer of Emendo Biotherapeutics, a next generation gene-editing company that was acquired in December 2020 by AnGes, Inc.

Silverstein previously operated in various senior executive corporate finance roles within Abeona Therapeutics, including Chief Financial Officer and Principal Financial Officer of the fully-integrated cell and gene therapy company, and continues to serve as a member of its Board of Directors. Prior to joining Abeona, she drove internal capital markets strategy within various public companies, including Relmada Therapeutics, Inc., a late-stage biotech company addressing diseases of the central nervous system (CNS). Silverstein also held senior executive roles within a New York-based biotechnology venture fund, SCO Capital Partners, and capital markets advisory firms, where she was instrumental in advising clients on transaction considerations and formulating effective US public listing and financing strategies.

Silverstein began her career in the financial services industry as an investment advisor with Royal Alliance Associates. A member of CHIEF and Women in Bio (WIB), two esteemed networks of exceptional female leaders, Silverstein holds a B.S from the Peter Tobin College of Business at St. John’s University and has earned various accreditations from the Financial Industry Regulatory Authority (FINRA).



  • CFO

    May, 2021 - present

View in org chart